The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
about
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 02 June 2016
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
@en
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
@nl
type
label
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
@en
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
@nl
prefLabel
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
@en
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo.
@nl
P2093
P2860
P50
P356
P1433
P1476
The HIV-derived protein Vpr52-96 has anti-glioma activity in vitro and in vivo
@en
P2093
Christian Schultz
Frank A Giordano
Frederik Wenz
Grit Welzel
Jens Kübler
Linda Hartmann
Manuela Felix
Marc A Brockmann
Marlon R Veldwijk
Patrick Maier
P2860
P304
45500-45512
P356
10.18632/ONCOTARGET.9787
P407
P577
2016-07-01T00:00:00Z